Concert Pharmaceuticals has announced that its Phase II clinical trial of CTP-692 as an adjunctive treatment in patients with schizophrenia failed to meet the primary endpoint or other secondary endpoints.

CTP-692 is a deuterated form of D-serine, an endogenous amino acid that is a co-agonist of the NMDA receptor.

The double-blind, randomised, placebo-controlled study analysed the safety and efficacy of CTP-692 as an adjunctive treatment in adult patients with schizophrenia.

The trial had 325 patients, who were on a stable course of an antipsychotic medication. They were randomly given either 1g, 2g, or 4g doses of CTP-692 or placebo once daily.

The change in the Positive and Negative Syndrome Scale (PANSS) total score at 12 weeks compared to baseline formed the trial’s primary endpoint.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Data from the trial showed that CTP-692 did not demonstrate a statistically significant improvement versus placebo at any of tested dose levels.

Furthermore, no significant improvements were noted in either the positive or negative symptoms subscales of the PANSS scale at any of the treatment doses.

CTP-692 treatment was generally well-tolerated in the Phase II trial while adverse events noted were mostly mild in severity and equally distributed across the dose groups, including placebo.

Concert Pharmaceuticals president and CEO Roger Tung said: “The body of evidence in the field supporting D-serine as an adjunctive treatment for schizophrenia was compelling and led us to advance CTP-692 into a Phase II proof of concept study.

“Unfortunately, we didn’t see the results we hoped for to support continuation of this programme.

“Going forward, we will focus our internal resources on the advancement of CTP-543, which is currently in Phase III evaluation for the treatment of alopecia areata, and evaluation of additional pipeline candidates.”

In June 2019, Concert Pharmaceuticals revealed plans to initiate a Phase II clinical trial of CTP-692 as an adjunctive treatment for schizophrenia, based on positive data from the Phase I programme.